Catalyst Biosciences Inc (CBIO, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions. Catalyst Biosciences Inc has a market cap of $312.200 million; its shares were traded at around $28.46 with and P/S ratio of 57.94.
For the last quarter Catalyst Biosciences Inc reported a revenue of $0.32 million, compared with the revenue of $0.07 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.02 million, an increase of 155.1% from last year. For the last five years Catalyst Biosciences Inc had an average revenue decline of 45.2% a year.
The reported loss per diluted share was $7.45 for the year, compared with the loss per share of $409.348 in the previous year. The Catalyst Biosciences Inc had an operating margin of -2143.61%, compared with the operating margin of -5117.29% a year before. The 10-year historical median operating margin of Catalyst Biosciences Inc is -217.68%. The profitability rank of the company is 2 (out of 10).
At the end of the fiscal year, Catalyst Biosciences Inc has the cash and cash equivalents of $14.5 million, compared with $10.3 million in the previous year. The company had no long term debt. Catalyst Biosciences Inc has a financial strength rank of 6 (out of 10).
At the current stock price of $28.46, Catalyst Biosciences Inc is traded at 545.4% premium to its historical median P/S valuation band of $4.41. The P/S ratio of the stock is 57.94, while the historical median P/S ratio is 8.99. The stock gained 412.38% during the past 12 months.
Directors and Officers Recent Trades:
- James E Flynn sold 71,778 shares of CBIO stock on 03/08/2018 at the average price of $30.53. The price of the stock has decreased by 6.78% since.
For the complete 20-year historical financial data of CBIO, click here.
